| Issue Type | XXXX |
|---|---|
| Country | Ireland |
| Industry | XXXX |
| Region | XXXX |
| Maturity Date | 2031-01-21 |
| Par Value | 100000 |
| Callable | XXXX |
| Next Call Date | XXXX |
| Call Type | XXXX |
| Call Price (%) | XXXX |
| Series | XXXX |
| Class | XXXX |
| Maturity Structure | XXXX |
| Amount Outstanding (mil) | 1000.00 |
| Coupon | 3.25 |
|---|---|
| Coupon Type | XXXX |
| Coupon Frequency | XXXX |
| First Coupon Date | XXXX |
| Last Coupon Date | XXXX |
| Sinking Fund | XXXX |
|---|---|
| Security | XXXX |
| Subordination | XXXX |
| Debt Type | XXXX |
| Issue Date | XXXX |
|---|---|
| Dated Date | XXXX |
| Issue Size (mil) | 1000.000 |
| Min. Piece | XXXX |
| Min. Increment | XXXX |
This Novo Nordisk Finance (Netherlands) B.V. corporate note has a X.X % fixed rate coupon paid on a XXXX basis. It was issued on MAR 12, 2000 with an issue size of XXX million USD and matures on DEC 9, 2000 with a last coupon date of FEB 28, 2020. |
Novo Nordisk Finance (Netherlands) B.V., founded in 1999 and based in Amsterdam, serves as the financing arm of Novo Nordisk A/S, a global leader in diabetes care and hormone replacement therapies. The company primarily focuses on providing financial support to its parent company's operations while managing a diverse portfolio of funding instruments.